catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Company profile
Ticker
CTLT
Exchange
Website
CEO
Alessandro Maselli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PTS Holdings Corp.
SEC CIK
Corporate docs
Subsidiaries
Catalent Anagni S.r.l. • Catalent Belgium S.A. • Catalent Belgium Holding S.A. • Catalent Brasil Ltda • Catalent China Holdings Limited • Catalent Cosmetics AG • Catalent CTS, LLC • Catalent CTS (Edinburgh) Limited • Catalent CTS (Kansas City), LLC • Catalent CTS (Singapore) Pvt Ltd ...
CTLT stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
8 May 24
8-K
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
8 May 24
DEFA14A
Additional proxy soliciting materials
3 May 24
8-K
Other Events
3 May 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEFM14A
Proxy related to merger
15 Apr 24
S-8
Registration of securities for employees
9 Apr 24
PREM14A
Preliminary proxy related to merger
3 Apr 24
8-K
Changes in Registrant's Certifying Accountant
1 Mar 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
Transcripts
CTLT
Earnings call transcript
2024 Q1
15 Nov 23
CTLT
Earnings call transcript
2023 Q4
29 Aug 23
CTLT
Earnings call transcript
2023 Q4
29 Aug 23
CTLT
Earnings call transcript
2023 Q3
12 Jun 23
CTLT
Earnings call transcript
2023 Q3
12 Jun 23
CTLT
Earnings call transcript
2023 Q3
19 May 23
CTLT
Earnings call transcript
2023 Q2
7 Feb 23
CTLT
Earnings call transcript
2023 Q1
1 Nov 22
CTLT
Earnings call transcript
2022 Q4
29 Aug 22
CTLT
Earnings call transcript
2022 Q3
3 May 22
Latest ownership filings
SC 13G/A
Capital World Investors
10 May 24
4
Scott Gunther
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
SC 13G
NOMURA HOLDINGS INC
14 Feb 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G/A
Veritas Asset Management LLP
12 Feb 24
SC 13G/A
Capital World Investors
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 209.00 mm | 209.00 mm | 209.00 mm | 209.00 mm | 209.00 mm | 209.00 mm |
Cash burn (monthly) | 23.67 mm | 6.00 mm | 265.67 mm | 93.17 mm | 23.33 mm | (no burn) |
Cash used (since last report) | 174.38 mm | 44.21 mm | 1.96 bn | 686.46 mm | 171.92 mm | n/a |
Cash remaining | 34.62 mm | 164.79 mm | -1.75 bn | -477.46 mm | 37.08 mm | n/a |
Runway (months of cash) | 1.5 | 27.5 | -6.6 | -5.1 | 1.6 | n/a |
Institutional ownership, Q4 2023
70.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 316 |
Opened positions | 43 |
Closed positions | 157 |
Increased positions | 99 |
Reduced positions | 130 |
13F shares | Current |
---|---|
Total value | 4.36 tn |
Total shares | 127.42 mm |
Total puts | 13.50 k |
Total calls | 164.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 20.19 mm | $906.98 bn |
Capital World Investors | 19.08 mm | $857.26 bn |
NMR Nomura | 11.49 mm | $516.13 bn |
T. Rowe Price | 8.43 mm | $378.64 mm |
Green Equity Investors VII | 7.83 mm | $781.37 mm |
STT State Street | 7.46 mm | $335.00 bn |
Veritas Asset Management | 6.47 mm | $0.00 |
IVZ Invesco | 3.82 mm | $171.69 bn |
BCS Barclays | 3.72 mm | $167.30 mm |
Capital International Investors | 2.99 mm | $134.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Gunther Scott | Common Stock | Sell | Dispose S | No | Yes | 56.2 | 387 | 21.75 k | 29,506 |
25 Jan 24 | Christa Kreuzburg | Common Stock | Payment of exercise | Dispose F | No | No | 50.41 | 523 | 26.36 k | 18,283 |
16 Jan 24 | Michael Hatzfeld | Common Stock | Grant | Acquire A | No | No | 0 | 6,071 | 0.00 | 7,908 |
16 Jan 24 | Michael Hatzfeld | Common Stock | Grant | Acquire A | No | No | 0 | 1,837 | 0.00 | 1,837 |
16 Jan 24 | Michael Hatzfeld | Options to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 49.42 | 3,981 | 196.74 k | 3,981 |
8 Dec 23 | Ricky Hopson | Common Stock | Payment of exercise | Dispose F | No | No | 37.18 | 256 | 9.52 k | 22,018 |
8 Dec 23 | Ricky Hopson | Common Stock | Grant | Acquire A | No | No | 0 | 747 | 0.00 | 22,274 |
News
Catalent Q3 EPS $(0.06) Misses $0.21 Estimate, Sales $1.07B Miss $1.12B Estimate
8 May 24
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
2 May 24
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
12 Apr 24
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
4 Apr 24
Stephens & Co. Reiterates Equal-Weight on Catalent, Maintains $63.5 Price Target
4 Apr 24
Press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN
10 May 24
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
8 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, HRT, CTLT
4 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, HRT, SWAV, MODN
2 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, ANSS, CTLT
29 Apr 24